Research Article
Open Access
Comparative Study of Efficacy and Safety of Ondansetron and Ramosetron in Patients Undergoing Hysterectomy
Pages 31 - 36
View PDF
Abstract
|
Introduction: Nausea and vomiting have been associated for many years with the use of general anaesthetics for surgical procedures. With the change in the emphasis from an inpatient to outpatient, hospital and office-based medical/surgical enhancement, there has been increased interest in the ‘big little problem of PONV(Postoperative nausea and vomiting). The newest class of antiemetics used for prevention and treatment of PONV (Postoperative nausea and vomiting) are serotonin (5-HT3) receptor antagonists–Ondansetron, Granisetron, Tropisetron, Dolasetron and Ramosetron. In the present study, intravenous ondansetron and Ramosetron were compared in the prevention of postoperative nausea and vomiting undergoing hysterectomy. Material and Methods: This clinical study consisting of 100 adult patients slated to undergo elective surgeries was undertaken at Fathima Institute of Medical Sciences. In this randomized, single blind clinical trial, we studied 100 patients between the ages of 23 and 65 years undergoing hysterectomy under general or spinal anaesthesia. Approval was taken from the ethical committee and written informed consent was taken from all the patients. They were randomly divided into two groups. Group I: Patients included in this group will receive Inj. Ondansetron 4 mg just before surgery and after 12 hr. Group II: Patients included in this group will receive Inj. Ramosetron 0.3mg just before surgery only. RESULTS : In our study, in initial 6 hours total 17 patients had nausea out of which 9 belonged to group I and 8 belonged to group II. When these groups were compared the difference was statistically non-significant (p>0.05). In next 6 to 24 hours 5 patients in group I and 4 in group II had nausea (p>0.05). However when the incidence of nausea was compared after 24 hours in group I (5 patients) and group II (1 patient) the difference was found to be statistically significant (p<0.05). Total number of patients in group I reporting nausea was 19 while it was 13 in group II, when compared it was found that group II has significantly lesser (p<0.05) occurrence of nausea. CONCLUSION: We have found that antiemetic therapy with Ramosetron at a dose of 0.3 mg is safer, well-tolerated, proved more effective and cheaper than Ondansetron 4 mg in the prevention of PONV.
|
Research Article
Open Access
Mesenchymal stromal cells for cardiovascular disease
Pages 21 - 30
View PDF
Abstract
The fields of regenerative medicine and cellular therapy have been the subject of tremendous hype and hope. In particular, the perceived usage of somatic cells like mesenchymal stromal cells (MSCs) has captured the imagination of many. MSCs are a rare population of cells found in multiple regions within the body that can be readily expanded ex vivo and utilized clinically. Originally, it was hypothesized that transplantation of MSCs to sites of injury would lead to de novo tissue-specific differentiation and thereby replace damaged tissue. Now, it is generally agreed that MSC home to sites of injury and direct positive remodeling via the secretion of paracrine factors. Consequently, their clinical utilization has largely revolved around their abilities to promote neovascularization for ischemic disorders and modulate overly exuberant inflammatory responses for autoimmune and alloimmune conditions. One of the major issues surrounding the development of somatic cell therapies like MSCs is that despite evoking a positive response, long-term engraftment and persistence of these cells is rare. Consequently, very large cell doses need be administered for raising production, delivery, and efficacy issues. In this review, we will outline the field of MSC in the context of ischemia and discuss causes for their lack of persistence. In addition, some of the methodologies be used to enhance their therapeutic potential will be highlighted.
Research Article
Open Access
Mesenchymal stromal cells for cardiovascular disease
Pages 11 - 20
View PDF
Abstract
The fields of regenerative medicine and cellular therapy have been the subject of tremendous hype and hope. In particular, the perceived usage of somatic cells like mesenchymal stromal cells (MSCs) has captured the imagination of many. MSCs are a rare population of cells found in multiple regions within the body that can be readily expanded ex vivo and utilized clinically. Originally, it was hypothesized that transplantation of MSCs to sites of injury would lead to de novo tissue-specific differentiation and thereby replace damaged tissue. Now, it is generally agreed that MSC home to sites of injury and direct positive remodeling via the secretion of paracrine factors. Consequently, their clinical utilization has largely revolved around their abilities to promote neovascularization for ischemic disorders and modulate overly exuberant inflammatory responses for autoimmune and alloimmune conditions. One of the major issues surrounding the development of somatic cell therapies like MSCs is that despite evoking a positive response, long-term engraftment and persistence of these cells is rare. Consequently, very large cell doses need be administered for raising production, delivery, and efficacy issues. In this review, we will outline the field of MSC in the context of ischemia and discuss causes for their lack of persistence. In addition, some of the methodologies be used to enhance their therapeutic potential will be highlighted.
Research Article
Open Access
NATURE: A Life Sustaining Factor
Pages 1 - 10
View PDF
Abstract
Environmental problems demand high attention today. A newborn baby is destined to claim only what his OR her predecessors have left. The bounty of nature is milked to such an extent that white dammar got dried up.
